Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03897374 · ClinicalTrials.gov registry record
Strategic Targeting for Optimal Prevention of Cancer
A clinical trial of Early Detection of Cancer, sponsored by ClinLogic.
- Recruiting
- Registry status
- 120,000
- Enrollment target
- 1
- Study location
NCT03897374: Recruiting study of Early Detection of Cancer, sponsored by ClinLogic.
NCT03897374 is a study of Early Detection of Cancer that is actively recruiting participants, run by ClinLogic. The registered enrollment target is 120,000 participants, above the 22,765-participant average among 8 other Early Detection of Cancer trials with a reported enrollment target (427% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03897374, a study of Early Detection of Cancer, is actively recruiting participants, sponsored by ClinLogic.
- RECRUITING
- Registry status
- 120,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary goal of the study is to record data over the observation period to evaluate the clinical benefit of using hereditary cancer genomic diagnostics to assess overall hereditary genetic cancer risk profile and to help guide physicians to pursue preventative measures, which may lead to early detection and treatment of the condition.
Primary Outcome
A study subject is known to have personal and/or family history of cancer known to be influenced by genetic variation.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Genetic Testing
Study Locations (1)
Texas
- Sunbeam Clinical - Prosper
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120,000 participants |
| Start Date | 2025-03-26 |
| Est. Completion | 2028-12-31 |
What NCT03897374 shows while recruiting
NCT03897374 is an observational study that tracks outcomes without assigning an intervention. Its 120,000 participants enrollment target places it among the larger protocols in the corpus, above the 22,765-participant average among 8 other Early Detection of Cancer trials with a reported enrollment target (427% higher).
The record links to 1 condition, with Early Detection of Cancer appearing as the primary indexed condition, and to 1 intervention - of which Genetic Testing is the first listed.
NCT03897374 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03897374 about?
NCT03897374 is a clinical study titled "Strategic Targeting for Optimal Prevention of Cancer". The primary goal of the study is to record data over the observation period to evaluate the clinical benefit of using hereditary cancer genomic diagnostics to assess overall hereditary genetic cancer risk profile and to help guide physicians to pursue preventative measures, which may lead to early d...
What is the current status of trial NCT03897374?
This trial is currently recruiting. The enrollment target is 120,000 participants. The study started on 2025-03-26. Estimated completion is 2028-12-31.
What conditions does trial NCT03897374 study?
This clinical trial studies the following conditions: Early Detection of Cancer.
What interventions are being tested in trial NCT03897374?
The interventions under investigation include: Genetic Testing (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03897374?
This trial is sponsored by ClinLogic, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03897374 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Early Detection of Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03897374's enrollment target sits among peer trials
120,000 1st of 8 higher than 8 of 8 other Early Detection of Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Detection of Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Caris Biorepository Research Protocol
RECRUITING
-
Integrating Telehealth to Advance Lung Cancer Screening
RECRUITING · NA
-
The FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI
RECRUITING · NA
-
Menstrual Cup for Early Endometrial Cancer Detection in Lynch Syndrome
RECRUITING · NA
-
Avera Cancer Sequencing and Analytics Protocol (ASAP)
RECRUITING
-
Epigenetic Signature for CRC Early Detection
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06608758 · 120,000 participants
End Diagnostic Overshadowing:Addressing Ableism in Diagnoses
- NCT06251323 · 119,680 participants · NA
Implementing Scalable, PAtient-centered, Team-based, Technology-enabled Care for Adults With Type 2 Diabetes (iPATH)
- NCT02693509 · 128,026 participants
Get With The Guidelines-Heart Failure Registry
- NCT05994482 · 130,000 participants
Surveillance Colonoscopy in Older Adults: The SurvOlderAdults Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI